Key Takeaways
- •Despite the FDA declaring an end to shortages of popular GLP-1 receptor agonists like Ozempic and Zepbound, compounded versions of these drugs remain widely available.
- •The FDA recently announced that the shortage of Ozempic (semaglutide) and Zepbound (tirzepatide) has been resolved.
- •Novo Nordisk, the manufacturer of Ozempic, and Eli Lilly, the maker of Zepbound, have both faced significant supply challenges over the past year.
Despite the FDA declaring an end to shortages of popular GLP-1 receptor agonists like Ozempic and Zepbound, compounded versions of these drugs remain widely available. This development has significant implications for peptide researchers, biohackers, and industry professionals monitoring the evolving landscape of peptide-based therapeutics.
The FDA Shortage Declaration and Its Aftermath
The FDA recently announced that the shortage of Ozempic (semaglutide) and Zepbound (tirzepatide) has been resolved. This decision typically triggers restrictions on compounding pharmacies, which had been legally producing copies of these drugs during the shortage period. However, early reports suggest that compounded versions are still being distributed, creating a complex regulatory environment.
Novo Nordisk, the manufacturer of Ozempic, and Eli Lilly, the maker of Zepbound, have both faced significant supply challenges over the past year. The shortage allowed compounding pharmacies to step in and fill the gap, offering lower-cost alternatives. According to sources, these compounded products remain popular among patients and researchers alike.
Implications for Peptide Research and Industry
For peptide researchers, the continued availability of compounded Ozempic and Zepbound presents both opportunities and challenges. Compounded versions may differ in purity, stability, and bioavailability compared to FDA-approved products. Researchers should exercise caution when sourcing these compounds for studies.
Industry professionals are watching closely as the FDA navigates this situation. The agency has historically taken action against compounding pharmacies that continue to produce drugs after a shortage ends, but enforcement has been inconsistent. This uncertainty affects supply chains and pricing for peptide-based therapies.
Volta Peptides offers a Peptide Purity Analyzer to help researchers assess the quality of their peptide samples, including compounded GLP-1 receptor agonists. Additionally, our Peptide Glossary provides definitions and context for key terms related to these compounds.
The Role of Major Players: Novo Nordisk and Eli Lilly
Novo Nordisk and Eli Lilly have invested heavily in expanding production capacity for their GLP-1 drugs. Novo Nordisk recently announced a proposed $1.8 billion acquisition of Swiss CDMO PolyPeptide, signaling its commitment to scaling up manufacturing. This move could eventually increase the supply of FDA-approved Ozempic and reduce reliance on compounded versions.
Eli Lilly has similarly ramped up production of Zepbound. However, the demand for these drugs continues to outstrip supply in some regions, which may explain why compounded versions remain available. According to sources, some patients and researchers prefer compounded products due to lower costs or customized dosing.
Regulatory and Safety Considerations
The FDA has expressed concerns about the safety and efficacy of compounded GLP-1 drugs. Compounded products are not subject to the same rigorous testing as FDA-approved medications, and there have been reports of adverse events associated with improperly compounded semaglutide and tirzepatide.
Researchers using compounded Ozempic or Zepbound should verify the source and purity of their compounds. Volta Peptides provides a Stability Calculator to help assess how storage conditions might affect peptide integrity. Additionally, the Interaction Checker-checker) can identify potential conflicts with other research compounds.
What This Means for the Future
The continued availability of compounded Ozempic and Zepbound despite the end of the shortage suggests that regulatory enforcement may be slow or uneven. This could lead to a prolonged period where both FDA-approved and compounded versions coexist in the market.
For peptide researchers, this means continued access to these compounds for study, but with a need for vigilance regarding quality control. Industry professionals should monitor FDA announcements and company news for updates on enforcement actions.
Volta Peptides remains committed to providing high-quality research compounds and educational resources. Visit our catalog to explore our range of peptides, and check our latest news for updates on regulatory developments.
Related Research Compounds
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg | >99% | 10mg | $49.00 |
| Tirzepatide 10mg | >99% | 10mg | $34.00 |
FAQ
What is Ozempic?
Ozempic is a brand-name prescription medication containing semaglutide, a GLP-1 receptor agonist. It is FDA-approved for improving blood sugar control in adults with type 2 diabetes and for reducing the risk of major cardiovascular events. It is manufactured by Novo Nordisk.
Is Ozempic safe?
Ozempic is generally considered safe when used as prescribed under medical supervision. Common side effects include nausea, vomiting, diarrhea, and constipation. More serious risks include pancreatitis, gallbladder disease, and kidney injury. It should not be used in patients with a personal or family history of medullary thyroid carcinoma.
What is Zepbound?
Zepbound is a brand-name prescription medication containing tirzepatide, a dual GIP and GLP-1 receptor agonist. It is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It is manufactured by Eli Lilly.